NCT03149679

The p53 Colorectal Cancer Trial

Treatment of Patients With Metastatic Colorectal Cancer Harboring TP53 Mutations With Dose-dense Cyclophosphamide - the p53 Colorectal Cancer Trial

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Haukeland University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Single center, open labeled, phase 2 clinical trial, where patients with metastatic colorectal cancer are selected for treatment with dose dense Cyclophosphamide every second week based on TP53 mutation status; i.e. only patients with TP53 mutated tumors may be included in the treatment arm.

Conditions

• Colorectal Cancer Metastatic
• Colorectal Cancer Stage IV
• TP53 Gene Mutation

Interventions

Type	Name	Description
DRUG	Cyclophosphamide	Chemotherapy

Timeline

• Start date: 2017-05-09
• Primary completion: 2020-08-07
• Completion: 2020-08-07
• First posted: 2017-05-11
• Last updated: 2021-01-22

Locations

1 site across 1 country: Norway